Yes, neomycin is ototoxic. Among the aminoglycoside antibiotics, it is considered the most toxic to hearing. Neomycin primarily damages the cochlea, the part of the inner ear responsible for converting sound into nerve signals, and the hearing loss it causes is typically permanent. The FDA requires labeling on neomycin-containing ear drops warning that the drug “can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti.”
How Neomycin Damages the Inner Ear
Neomycin reaches the inner ear through the bloodstream, crossing the blood-labyrinth barrier into the fluid-filled chambers of the cochlea. Once there, it enters hair cells, the tiny sensory cells that detect sound vibrations, through channels on their surface that normally let in calcium and other small ions. These channels are large enough for neomycin molecules to pass through, and the drug essentially competes with calcium for entry.
The problem is that once neomycin gets inside a hair cell, it can’t get back out. The internal structure of the channel creates an energy barrier that traps the drug inside. From there, neomycin causes damage through several pathways. It disrupts the cell’s ability to regulate its electrical charge, leaving it in a state of sustained activation that contributes to cell death. It also interferes with mitochondria, the energy-producing structures inside cells, triggering the release of toxic free radicals and setting off a chain of events that ultimately kills the cell.
Damage starts at the base of the cochlea, the region responsible for detecting high-frequency sounds. This is why high-pitched hearing goes first. If exposure continues, the destruction spreads toward the parts of the cochlea that handle lower frequencies, including the range used for speech. Even in areas where hair cells survive, neomycin can degrade the tiny structures that relay signals to the auditory nerve, reducing hearing function in ways that aren’t visible under a microscope.
Early Warning Signs
The earliest symptom of neomycin-related damage is often tinnitus, a ringing or buzzing sound in the ears. Initial hearing loss typically occurs at frequencies above 4,000 Hz, well above the range of normal conversation. Because of this, many people don’t notice the damage at first. A standard hearing test that includes high-frequency ranges can catch it before it progresses.
If the drug isn’t stopped, hearing loss moves into the speech frequency range, and in severe cases, a person can become profoundly deaf. Some patients also develop vestibular symptoms, meaning problems with balance. Early signs of vestibular injury include nystagmus (involuntary eye movements) and a sense of unsteadiness, particularly with changes in head position.
Systemic vs. Topical Risk
Neomycin is rarely given by injection today precisely because of its ototoxicity, but it’s still used orally (to reduce bacteria in the gut before bowel surgery, for example) and topically in ear drops. The risk profile differs depending on how the drug enters the body.
Oral neomycin is generally considered low risk because very little is absorbed from the gut into the bloodstream. One prospective study of 30 adults taking oral neomycin long-term found ototoxicity in only 2 of the 30 subjects. However, a study in children found significant hearing loss in 9 out of 17 participants in the 2,000 to 8,000 Hz range, suggesting the risk may be higher than once assumed, particularly in younger patients.
Topical neomycin ear drops pose a specific concern when the eardrum is not intact. A perforated eardrum allows the drug to pass directly into the middle ear and potentially reach the inner ear at much higher concentrations than it would through the bloodstream. FDA labeling for neomycin-containing ear drops explicitly states they should not be used in patients with a perforated eardrum. Cases of profound, irreversible hearing loss have been documented from topical use alone.
Who Is at Higher Risk
Kidney function is the single biggest risk factor. Neomycin is cleared from the body through the kidneys, so impaired kidney function allows the drug to accumulate to dangerous levels. Published case reports describe severe, permanent hearing loss in patients with chronic renal failure who received topical neomycin. Prolonged use also increases risk. FDA labeling recommends limiting treatment to no more than 10 consecutive days.
Certain genetic factors can also increase vulnerability. Some people carry mitochondrial DNA mutations that make their hair cells especially susceptible to aminoglycoside damage. For these individuals, even a single standard course of treatment can cause significant hearing loss.
Is the Damage Reversible?
In most cases, no. Neomycin-induced hearing loss is described in the clinical literature as irreversible. Human hair cells do not regenerate. Once they are destroyed, the hearing loss is permanent. This is what distinguishes ototoxic hearing loss from many other drug side effects: there is no recovery period, and stopping the drug after damage has occurred does not restore function. It only prevents further progression.
Safer Alternatives for Ear Infections
Fluoroquinolone ear drops, specifically ciprofloxacin and ofloxacin, have no demonstrated ototoxicity in studies of both adults and children. They are now widely recognized as safe for the cochlea and are effective against the bacteria most commonly responsible for chronic ear infections, including Pseudomonas. In head-to-head comparisons, topical ciprofloxacin outperformed both neomycin and gentamicin in treating chronic suppurative otitis media, proving both safer and more effective.
In one trial, all 20 patients treated with ciprofloxacin ear drops showed clinical improvement, compared to only 6 of 20 patients using gentamicin. No cochlear or vestibular toxicity was detected. Another trial of ciprofloxacin in children found that the drug was not even detectable in blood plasma, confirming that systemic absorption from ear drops is negligible. Current clinical guidance recommends fluoroquinolone drops as the first-line topical treatment for ear infections, especially when the eardrum may be compromised.